Compare DAVA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAVA | SLN |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.2M | 318.4M |
| IPO Year | 2018 | N/A |
| Metric | DAVA | SLN |
|---|---|---|
| Price | $6.74 | $6.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $16.33 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 1.6M | 280.4K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.26 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,015,391,026.00 | $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | 1.07 | ★ 40.39 |
| 52 Week Low | $6.02 | $1.97 |
| 52 Week High | $34.94 | $8.88 |
| Indicator | DAVA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 56.90 |
| Support Level | $6.02 | $5.98 |
| Resistance Level | $6.54 | $6.88 |
| Average True Range (ATR) | 0.26 | 0.52 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 80.12 | 71.63 |
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.